Diamyd Medical Completes Patient Enrollment In Phase III Diamyd Vaccine Study

Diamyd Medical has completed patient recruitment in European Phase III study of the diabetes vaccine Diamyd. It is estimated that results from the study can be reported during spring 2011.

Reportedly, 320 children and adolescents between 10 and 20 years of age and recently diagnosed with type 1 diabetes have now been identified and included in the European Phase III study and have received their first injection of the Diamyd vaccine or placebo.

The study aims to investigate whether the Diamyd vaccine can halt or slow the destruction of beta cells in the pancreas in type 1 diabetes, preserving the body’s own ability to control blood sugar levels.

The Diamyd vaccine has shown in Phase II studies, to halt or slow the destruction process and preserve the remaining beta cell function.

The company said that in the US, a parallel Phase III study (DIAPREVENT) is ongoing. The study was recently opened for children as young as 10 years of age. The company has also invested in expanded recruitment activities in connection to an increase in the number of participating pediatric diabetes clinics.

Elisabeth Lindner, president and CEO of Diamyd Medicalm, said: “It is clear now that we will be able to present results from the study during spring 2011 and our schedule for the market application thereby remains unchanged.”